Clearwater Capital Advisors LLC Buys 48,700 Shares of ImmunityBio, Inc. (NASDAQ:IBRX)

Clearwater Capital Advisors LLC lifted its position in shares of ImmunityBio, Inc. (NASDAQ:IBRX) by 12.3% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 443,299 shares of the company’s stock after acquiring an additional 48,700 shares during the quarter. Clearwater Capital Advisors LLC owned approximately 0.07% of ImmunityBio worth $2,225,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the company. Aire Advisors LLC bought a new position in ImmunityBio during the third quarter worth about $25,000. WINTON GROUP Ltd bought a new stake in ImmunityBio during the 3rd quarter valued at $26,000. Vanguard Personalized Indexing Management LLC purchased a new stake in shares of ImmunityBio during the third quarter worth $37,000. Private Advisor Group LLC bought a new position in shares of ImmunityBio in the fourth quarter worth $53,000. Finally, SG Americas Securities LLC purchased a new position in shares of ImmunityBio in the third quarter valued at $57,000. Hedge funds and other institutional investors own 8.58% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Piper Sandler raised their target price on ImmunityBio from $5.00 to $6.00 and gave the stock a “neutral” rating in a research note on Monday, April 29th.

ImmunityBio Stock Performance

ImmunityBio stock traded up $0.15 during midday trading on Thursday, reaching $8.07. 3,034,524 shares of the stock were exchanged, compared to its average volume of 6,065,369. The company’s fifty day moving average is $5.88 and its 200-day moving average is $4.61. ImmunityBio, Inc. has a 52 week low of $1.25 and a 52 week high of $10.53. The firm has a market cap of $5.46 billion, a PE ratio of -6.83 and a beta of 1.16.

ImmunityBio (NASDAQ:IBRX) last posted its quarterly earnings data on Tuesday, March 19th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.01). The company had revenue of $0.14 million during the quarter, compared to the consensus estimate of $0.03 million. On average, sell-side analysts anticipate that ImmunityBio, Inc. will post -0.76 earnings per share for the current fiscal year.

ImmunityBio Company Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in discovering, developing, and commercializing next-generation immuno- and cellular therapies for cancer and infectious diseases in the United States and Europe. The company offers immunotherapy and cell therapy platforms, including antibody cytokine fusion protein N-803, vaccine delivery technologies, and natural killer cell therapies.